Quantitative automated microscopy (QuAM) elucidates growth factor specific signalling in pain sensitization

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Andres, Christine ^a,b   Meyer, Sonja ^c   Dina, Olayinka A ^d   Levine, Jon D ^d   Hucho, Tim ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; PROSTAGLANDIN E2; STAT3 PROTEIN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ANIMAL CELL; ANTINOCICEPTION; ARTICLE; AUTOMATION; CELL ADHESION; CELL CULTURE; CELL DIFFERENTIATION; CELL REGENERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE LOCATION; GENE TRANSLOCATION; HYPERALGESIA; MALE; MICROSCOPY; NOCICEPTION; NONHUMAN; PAIN SENSITIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RAT; SENSITIZATION; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; SPINAL GANGLION; ANIMAL; COMPUTER PROGRAM; METABOLISM; METHODOLOGY; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY RECEPTOR; SPRAGUE DAWLEY RAT;

ANIMALS; CELLS, CULTURED; EPIDERMAL GROWTH FACTOR; GANGLIA, SPINAL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICROSCOPY; NERVE GROWTH FACTOR; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; SENSORY RECEPTOR CELLS; SIGNAL TRANSDUCTION; SOFTWARE;

EID: 78650427470     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-6-98     Document Type: Article

References (69)

1. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001, 413:203-210. 10.1038/35093019, 11557989.
2. Price TJ, Flores CM. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. J Pain 2007, 8:263-272. 10.1016/j.jpain.2006.09.005, 1899162, 17113352.
3. Kashiba H, Uchida Y, Senba E. Difference in binding by isolectin B4 to trkA and c-ret mRNA-expressing neurons in rat sensory ganglia. Brain Res Mol Brain Res 2001, 95:18-26. 10.1016/S0169-328X(01)00224-8, 11687273.
4. Orozco OE, Walus L, Sah DW, Pepinsky RB, Sanicola M. GFRalpha3 is expressed predominantly in nociceptive sensory neurons. Eur J Neurosci 2001, 13:2177-2182. 10.1046/j.0953-816x.2001.01596.x, 11422460.
5. Molliver DC, Radeke MJ, Feinstein SC, Snider WD. Presence or absence of TrkA protein distinguishes subsets of small sensory neurons with unique cytochemical characteristics and dorsal horn projections. J Comp Neurol 1995, 361:404-416. 10.1002/cne.903610305, 8550888.
6. Fang X, Djouhri L, McMullan S, Berry C, Okuse K, Waxman SG, Lawson SN. trkA is expressed in nociceptive neurons and influences electrophysiological properties via Nav1.8 expression in rapidly conducting nociceptors. J Neurosci 2005, 25:4868-4878. 10.1523/JNEUROSCI.0249-05.2005, 15888662.
7. Ji RR, Strichartz G. Cell signalling and the genesis of neuropathic pain. Sci STKE 2004, 2004:reE14. 10.1126/stke.2522004re14, 15454629.
8. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. Embo J 2005, 24:4211-4223. 10.1038/sj.emboj.7600893, 1356334, 16319926.
9. Hucho T, Levine JD. Signalling pathways in sensitization: toward a nociceptor cell biology. Neuron 2007, 55:365-376. 10.1016/j.neuron.2007.07.008, 17678851.
10. Donnerer J. Regeneration of primary sensory neurons. Pharmacology 2003, 67:169-181. 10.1159/000068405, 12595748.
11. Lykissas MG, Batistatou AK, Charalabopoulos KA, Beris AE. The role of neurotrophins in axonal growth, guidance, and regeneration. Curr Neurovasc Res 2007, 4:143-151. 10.2174/156720207780637216, 17504212.
12. Liuzzi FJ, Tedeschi B. Peripheral nerve regeneration. Neurosurg Clin N Am 1991, 2:31-42.
13. Devor M, Govrin-Lippmann R. Neurogenesis in adult rat dorsal root ganglia. Neurosci Lett 1985, 61:189-194. 10.1016/0304-3940(85)90423-9, 4080254.
14. Takuma K, Yoshida T, Lee E, Mori K, Kishi T, Baba A, Matsuda T. CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. Eur J Pharmacol 2000, 406:333-339. 10.1016/S0014-2999(00)00701-9, 11040339.
15. Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: ON or OFF the Trks?. Mol Interv 2007, 7:26-41. 10.1124/mi.7.1.6, 17339604.
16. Bennett DL, Michael GJ, Ramachandran N, Munson JB, Averill S, Yan Q, McMahon SB, Priestley JV. A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury. J Neurosci 1998, 18:3059-3072.
17. Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000, 290:124-127. 10.1126/science.290.5489.124, 11021795.
18. Fang M, Wang Y, He QH, Sun YX, Deng LB, Wang XM, Han JS. Glial cell line-derived neurotrophic factor contributes to delayed inflammatory hyperalgesia in adjuvant rat pain model. Neuroscience 2003, 117:503-512. 10.1016/S0306-4522(02)00958-2, 12617957.
19. Bogen O, Joseph EK, Chen X, Levine JD. GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signalling and dependent on the IB4-binding protein versican. Eur J Neurosci 2008, 28:12-19. 10.1111/j.1460-9568.2008.06308.x, 2660608, 18616564.
20. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000, 10:381-391. 10.1016/S0959-4388(00)00092-1, 10851172.
21. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24:677-736. 10.1146/annurev.neuro.24.1.677, 2758233, 11520916.
22. Malik-Hall M, Dina OA, Levine JD. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 2005, 21:3387-3394. 10.1111/j.1460-9568.2005.04173.x, 16026476.
23. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16:585-601. 10.1111/j.1524-475X.2008.00410.x, 19128254.
24. Shiraha H, Glading A, Gupta K, Wells A. IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J Cell Biol 1999, 146:243-254. 2199733, 10402474.
25. Schultz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 1991, 45:346-352. 10.1002/jcb.240450407, 2045428.
26. Dogan S, Demirer S, Kepenekci I, Erkek B, Kiziltay A, Hasirci N, Muftuoglu S, Nazikoglu A, Renda N, Dincer UD, et al. Epidermal growth factor-containing wound closure enhances wound healing in non-diabetic and diabetic rats. Int Wound J 2009, 6:107-115. 10.1111/j.1742-481X.2009.00584.x, 19432660.
27. Hardwicke J, Schmaljohann D, Boyce D, Thomas D. Epidermal growth factor therapy and wound healing--past, present and future perspectives. Surgeon 2008, 6:172-177. 10.1016/S1479-666X(08)80114-X, 18581754.
28. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003, 284:31-53. 10.1016/S0014-4827(02)00098-8, 12648464.
29. Marshall CJ. Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185. 10.1016/0092-8674(95)90401-8, 7834738.
30. Santos SD, Verveer PJ, Bastiaens PI. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 2007, 9:324-330. 10.1038/ncb1543, 17310240.
31. Hucho TB, Dina OA, Levine JD. Epac mediates a cAMP-to-PKC signalling in inflammatory pain: an isolectin B4(+) neuron-specific mechanism. J Neurosci 2005, 25:6119-6126. 10.1523/JNEUROSCI.0285-05.2005, 15987941.
32. Taiwo YO, Coderre TJ, Levine JD. The contribution of training to sensitivity in the nociceptive paw-withdrawal test. Brain Res 1989, 487:148-151. 10.1016/0006-8993(89)90950-5, 2752281.
33. Dina OA, McCarter GC, de Coupade C, Levine JD. Role of the sensory neuron cytoskeleton in second messenger signalling for inflammatory pain. Neuron 2003, 39:613-624. 10.1016/S0896-6273(03)00473-2, 12925276.
34. Khasar SG, Lin YH, Martin A, Dadgar J, McMahon T, Wang D, Hundle B, Aley KO, Isenberg W, McCarter G, et al. A novel nociceptor signalling pathway revealed in protein kinase C epsilon mutant mice. Neuron 1999, 24:253-260. 10.1016/S0896-6273(00)80837-5, 10677042.
35. Khasar SG, Ouseph AK, Chou B, Ho T, Green PG, Levine JD. Is there more than one prostaglandin E receptor subtype mediating hyperalgesia in the rat hindpaw?. Neuroscience 1995, 64:1161-1165. 10.1016/0306-4522(94)00423-3, 7753383.
36. Ji RR, Gereau R, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009, 60:135-148. 10.1016/j.brainresrev.2008.12.011, 2666786, 19150373.
37. Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, Yan Q, Snider WD. IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron 1997, 19:849-861. 10.1016/S0896-6273(00)80966-6, 9354331.
38. Averill S, Delcroix JD, Michael GJ, Tomlinson DR, Fernyhough P, Priestley JV. Nerve growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult nociceptive neurones. Mol Cell Neurosci 2001, 18:183-196. 10.1006/mcne.2001.1015, 11520179.
39. Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signalling specificity. J Cell Sci 2005, 118:2997-3002. 10.1242/jcs.02505, 16014377.
40. Wong RW, Guillaud L. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev 2004, 15:147-156. 10.1016/j.cytogfr.2004.01.004, 15110798.
41. Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci 1995, 7:1484-1494. 10.1111/j.1460-9568.1995.tb01143.x, 2758238, 7551174.
42. Diaz-Meco MT, Moscat J. MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signalling. Mol Cell Biol 2001, 21:1218-1227. 10.1128/MCB.21.4.1218-1227.2001, 99575, 11158308.
43. Kao S, Jaiswal RK, Kolch W, Landreth GE. Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem 2001, 276:18169-18177. 10.1074/jbc.M008870200, 11278445.
44. Peavy RD, Chang MS, Sanders-Bush E, Conn PJ. Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J Neurosci 2001, 21:9619-9628.
45. Jeon SH, Yoon JY, Park YN, Jeong WJ, Kim S, Jho EH, Surh YJ, Choi KY. Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin. J Biol Chem 2007, 282:14482-14492. 10.1074/jbc.M611129200, 17374607.
46. Sauvant C, Hesse D, Holzinger H, Evans KK, Dantzler WH, Gekle M. Action of EGF and PGE2 on basolateral organic anion uptake in rabbit proximal renal tubules and hOAT1 expressed in human kidney epithelial cells. Am J Physiol Renal Physiol 2004, 286:F774-783. 10.1152/ajprenal.00326.2003, 14644751.
47. Lucas TF, Siu ER, Esteves CA, Monteiro HP, Oliveira CA, Porto CS, Lazari MF. 17beta-estradiol induces the translocation of the estrogen receptors ESR1 and ESR2 to the cell membrane, MAPK3/1 phosphorylation and proliferation of cultured immature rat Sertoli cells. Biol Reprod 2008, 78:101-114. 10.1095/biolreprod.107.063909, 17928626.
48. Taiwo YO, Levine JD. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991, 44:131-135. 10.1016/0306-4522(91)90255-M, 1722888.
49. Lang P, Yeow K, Nichols A, Scheer A. Cellular imaging in drug discovery. Nat Rev Drug Discov 2006, 5:343-356. 10.1038/nrd2008, 16582878.
50. Bowen WP, Wylie PG. Application of laser-scanning fluorescence microplate cytometry in high content screening. Assay Drug Dev Technol 2006, 4:209-221. 10.1089/adt.2006.4.209, 16712425.
51. Russello SV. Assessing cellular protein phosphorylation: high throughput drug discovery technologies. Assay Drug Dev Technol 2004, 2:225-235. 10.1089/154065804323056567, 15165518.
52. Lu SG, Zhang X, Gold MS. Intracellular calcium regulation among subpopulations of rat dorsal root ganglion neurons. J Physiol 2006, 577:169-190. 10.1113/jphysiol.2006.116418, 2000672, 16945973.
53. Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 2006, 103:8245-8250. 10.1073/pnas.0602813103, 1472458, 16702558.
54. Vial E, Marshall CJ. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J Cell Sci 2003, 116:4957-4963. 10.1242/jcs.00812, 14625389.
55. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. Embo J 1999, 18:664-674. 10.1093/emboj/18.3.664, 1171159, 9927426.
56. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 1998, 8:1141-1150. 10.1016/S0960-9822(07)00485-X, 9799732.
57. Choi JS, Hudmon A, Waxman SG, Dib-Hajj SD. Calmodulin regulates current density and frequency-dependent inhibition of sodium channel Nav1.8 in DRG neurons. J Neurophysiol 2006, 96:97-108. 10.1152/jn.00854.2005, 16598065.
58. Fang X, Djouhri L, McMullan S, Berry C, Waxman SG, Okuse K, Lawson SN. Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. J Neurosci 2006, 26:7281-7292. 10.1523/JNEUROSCI.1072-06.2006, 16822986.
59. Werner MH, Nanney LB, Stoscheck CM, King LE. Localization of immunoreactive epidermal growth factor receptors in human nervous system. J Histochem Cytochem 1988, 36:81-86.
60. Huerta JJ, Diaz-Trelles R, Naves FJ, Llamosas MM, Del Valle ME, Vega JA. Epidermal growth factor receptor in adult human dorsal root ganglia. Anat Embryol (Berl) 1996, 194:253-257.
61. Nilsson A, Kanje M. Amphiregulin acts as an autocrine survival factor for adult sensory neurons. Neuroreport 2005, 16:213-218. 10.1097/00001756-200502280-00002, 15706222.
62. Chalazonitis A, Kessler JA, Twardzik DR, Morrison RS. Transforming growth factor alpha, but not epidermal growth factor, promotes the survival of sensory neurons in vitro. J Neurosci 1992, 12:583-594.
63. Woodall AJ, Richards MA, Turner DJ, Fitzgerald EM. Growth factors differentially regulate neuronal Cav channels via ERK-dependent signalling. Cell Calcium 2008, 43:562-575. 10.1016/j.ceca.2007.10.001, 17996937.
64. Khasar SG, McCarter G, Levine JD. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 1999, 81:1104-1112.
65. Aley KO, Martin A, McMahon T, Mok J, Levine JD, Messing RO. Nociceptor sensitization by extracellular signal-regulated kinases. J Neurosci 2001, 21:6933-6939.
66. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, Morelli MP, Cascone T, Tortora G. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006, 17(Suppl 7):vii109-114. 10.1093/annonc/mdl962, 16760272.
67. Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E. Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 2005, 23:8757-8764. 10.1200/JCO.2005.01.9521, 16314636.
68. Folprecht G, Tabernero J, Kohne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, et al. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin Cancer Res 2008, 14:215-223. 10.1158/1078-0432.CCR-07-1053, 18172273.
69. Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003, 14:1346-1363. 10.1093/annonc/mdg365, 12954573.